Acurx Pharmaceuticals (ACXP) News Today $0.43 -0.01 (-1.25%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$0.42 0.00 (-0.12%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period HC Wainwright Brokers Raise Earnings Estimates for ACXPMarch 23 at 1:33 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for ACXP FY2029 Earnings?March 22, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Acurx Pharmaceuticals (NASDAQ:ACXP)March 21, 2025 | americanbankingnews.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comAcurx reports Q4 EPS (16c) vs. (37c) last yearMarch 18, 2025 | markets.businessinsider.comAcurx price target lowered to $5 from $14 at Alliance Global PartnersMarch 18, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | seekingalpha.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateMarch 18, 2025 | prnewswire.comAcurx Pharmaceuticals (ACXP) to Release Earnings on TuesdayMarch 16, 2025 | americanbankingnews.comAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingMarch 10, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingMarch 10, 2025 | investing.comAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingMarch 10, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct OfferingMarch 7, 2025 | gurufocus.comAcurx to sell 2.745M shares at 40c in registered direct offeringMarch 7, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct OfferingMarch 7, 2025 | prnewswire.comAcurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI AntibioticsMarch 3, 2025 | prnewswire.comAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business UpdateFebruary 28, 2025 | prnewswire.comAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDIFebruary 24, 2025 | prnewswire.comAcurx new patent granted by JPO related to DNA Polymerase IIIC InhibitorsFebruary 19, 2025 | markets.businessinsider.comJPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC InhibitorsFebruary 19, 2025 | prnewswire.comAcurx files to sell 2.61M shares of common stock for holdersJanuary 31, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Joseph C. Scodari Buys 24,631 SharesJanuary 9, 2025 | insidertrades.comAcurx receives positive EMA guidance for ibezapolstat Phase 3 programJanuary 7, 2025 | markets.businessinsider.comAcurx to sell 2.46M shares at $1.015 in registered direct offeringJanuary 7, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 7, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 6, 2025 | investing.comAcurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 6, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc.: Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)January 6, 2025 | finanznachrichten.deAcurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)January 6, 2025 | prnewswire.comOptimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Ibezapolstat Progress and Strategic Financial PlanningDecember 12, 2024 | markets.businessinsider.comAcurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsDecember 9, 2024 | prnewswire.comAcurx Pharmaceuticals (NASDAQ:ACXP) Stock, Insider Trading ActivityNovember 22, 2024 | benzinga.comAcurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin InvestmentNovember 20, 2024 | marketwatch.comAcurx board approves Bitcoin as treasury reserve assetNovember 20, 2024 | markets.businessinsider.comAcurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbookNovember 20, 2024 | cnbc.comAcurx Pharmaceuticals, Inc.: Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNovember 20, 2024 | finanznachrichten.deAcurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNovember 20, 2024 | prnewswire.comAcurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data UpdateNovember 18, 2024 | prnewswire.comPromising Prospects for Acurx Pharmaceuticals: Buy Rating Backed by Ibezapolstat’s Efficacy and Strategic PositioningNovember 15, 2024 | markets.businessinsider.comAcurx Pharmaceuticals Inc (ACXP) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...November 14, 2024 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comAcurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business UpdateNovember 13, 2024 | prnewswire.comAcurx reports positive Phase 2 results for CDI treatment ibezapolstatOctober 24, 2024 | uk.investing.comAcurx’s ibezapostat shows favorable effect in Phase 2b CDI trialOctober 22, 2024 | markets.businessinsider.comAcurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific ConferenceOctober 21, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor EngagementOctober 17, 2024 | prnewswire.comAcurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024October 16, 2024 | prnewswire.comAcurx Pharmaceuticals (NASDAQ:ACXP) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.comAcurx reports ibezapolstat's positive microbiome effects and Anthrax activitySeptember 29, 2024 | uk.investing.com Remove Ads Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address ACXP Media Mentions By Week ACXP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACXP News Sentiment▼0.720.79▲Average Medical News Sentiment ACXP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACXP Articles This Week▼121▲ACXP Articles Average Week Remove Ads Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Reviva Pharmaceuticals News FibroBiologics News Alterity Therapeutics News OS Therapies News Celularity News Cadrenal Therapeutics News Generation Bio News Forte Biosciences News Medicus Pharma News CASI Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACXP) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
